The TEXT and SOFT trials have subsequently demonstrated that compared with tamoxifen, exemestane given alongside OS improved DFS and reduced risk of recurrence in pre-menopausal patients with human epidermal growth factor receptor 2 negative (HER2-) HR+BC [2,7]. This evidence concerns the gene ERBB2 and breast cancer.